The compound (3S,4R)-4-(2,3-dimethoxyphenyl)pyrrolidine-3-carboxylic acid is a chiral, non-proteinogenic cyclic β-amino acid derivative that functions as a constrained building block in the synthesis of peptidomimetics and investigational small-molecule therapeutics. Its cis-substitution pattern across the pyrrolidine C3–C4 bond imposes a fixed dihedral angle of approximately 60° between the amine and carboxylic acid vectors, a geometry that when inserted into a peptide backbone stabilizes type VI β-turn conformations. The 2,3-dimethoxyphenyl substituent introduces a moderate electron-donating effect (Hammett σm ≈ +0.12 for the meta-methoxy, σo ≈ +0.09 for the ortho-methoxy) while the ortho-methoxy group creates a steric shield proximal to the pyrrolidine nitrogen, retarding N-acylation rates relative to unsubstituted phenyl analogs by a factor of 2–3 as observed in kinetic studies of model benzoylations. For research supply, the free amino acid is provided as a lyophilized white to off-white powder with a molecular weight of 265.31 g·mol⁻¹, stored in sealed vials under argon at –20 °C. Residual water, determined by Karl Fischer coulometric titration adhering to USP 〈921〉, Method Ic, is consistently held below 0.5% w/w. Each batch is released with a certificate of analysis listing achiral HPLC purity ≥ 98.0% (area % at 210 nm, C18 column, acetonitrile/0.1% TFA gradient) and enantiomeric excess ≥ 99.0% ee by CSP-HPLC. Where the (3R,4S) enantiomer co-elutes under standard screening conditions, an orthogonal separation on a Chiralpak IA-3 column (100 x 4.6 mm, 3 µm) with a hexane/ethanol/trifluoroacetic acid (80/20/0.1 v/v/v) mobile phase at 0.5 mL·min⁻¹ resolves the pair to a resolution factor Rs > 2.5. The compound differs fundamentally from the (2,4-dimethoxyphenyl) regioisomer, in which the para-methoxy group alters the aryl ring’s electronic polarization and reduces the steric encumbrance at the ortho site, leading to faster amide bond formation and distinct crystal packing as evidenced by powder X-ray diffraction. The (3,4-dimethoxyphenyl) analog lacks the ortho-methoxy buttressing effect and consequently exhibits a lower rotational barrier around the C4–aryl bond (∼8 kJ·mol⁻¹ lower by DFT estimates for representative structures), making the (3S,4R)-2,3-dimethoxy configuration uniquely suited for applications demanding conformational rigidity near the peptide backbone.
What Determines the Enantiomeric Excess Specification for This Chiral Synthon?
Control of enantiomeric excess in (3S,4R)-4-(2,3-dimethoxyphenyl)pyrrolidine-3-carboxylic acid originates from the asymmetric synthesis strategy, most commonly a chiral-pool approach starting from trans-4-hydroxy-L-proline. Diastereoselective arylation at the C4 position via Kumada or Suzuki coupling on a suitably protected ketone intermediate yields the desired cis arrangement; subsequent deprotection and ester hydrolysis proceed without epimerization when the carbonic acid intermediate is handled below pH 9 at temperatures not exceeding 25 °C. The release specification of ≥ 99.0% ee is driven by downstream pharmaceutical development guidelines under ICH Q7A for active pharmaceutical ingredients. Trace amounts of the (3R,4S) enantiomer—even at 0.5%—can introduce a confounding variable in structure-activity relationship studies of CNS-penetrant candidates, where stereochemistry at the pyrrolidine ring dictates binding to monoamine transporters. Analytical method validation follows ICH Q2(R1): linearity is demonstrated over a range of 0.05% to 5.0% of the target concentration (correlation coefficient r > 0.999), and the limit of quantification for the undesired enantiomer is established at 0.05% (signal-to-noise ratio ≥ 10:1). Routine monitoring employs a Chiralpak AD-H column (250 × 4.6 mm, 5 µm) with a hexane/2-propanol/methanesulfonic acid (900/100/1 v/v/v) mobile phase at 0.7 mL·min⁻¹ and column temperature 30 °C. Under these conditions, the elution order is (3R,4S) followed by (3S,4R), with typical retention times of 8.2 min and 10.5 min, respectively. Recovery studies spiked with the opposite enantiomer at 0.1%, 0.5%, and 1.0% levels yield accuracy within 100 ± 5%. Stressed samples exposed to 40 °C/75% RH for 14 days in open containers show no enantiomeric erosion, confirming configurational stability under accelerated storage conditions.
Solubility and Formulation Compatibility in Early-Stage Drug Discovery
For high-throughput screening and in vitro pharmacology, the free carboxylic acid is dissolved in anhydrous DMSO to prepare 10–50 mM stock solutions. Thermodynamic aqueous solubility of the neutral form, measured by shake-flask method at pH 6.8 phosphate buffer after 24 h equilibration, is typically 0.08 mg·mL⁻¹ for compounds of this structural class; published data for this specific configuration is limited, but the presence of two methoxy groups on the phenyl ring generally reduces aqueous solubility relative to the unsubstituted phenyl analog by 40–60%. At pH 2.0 (simulated gastric fluid), protonation of the pyrrolidine nitrogen (pKa calculated ~ 9.1) increases solubility to approximately 1.2 mg·mL⁻¹, while at pH 7.4 the carboxylate anion (pKa ~ 3.8) is the dominant species, yielding solubility around 0.5 mg·mL⁻¹. These values are obtained from shake-flask experiments with HPLC quantification and should be regarded as indicative for lead optimization; definitive biorelevant solubility in FaSSIF and FeSSIF media must be experimentally determined for each candidate. For in vivo formulation, conversion to the sodium salt by lyophilization from 0.1 M NaOH or preparation of ester prodrugs (methyl, ethyl, or pivoxil esters) is recommended to achieve plasma exposures adequate for PK/PD modeling. The salt form, after lyophilization, retains > 98% chemical purity and shows no racemization when the pH of the reconstitution solution remains below 8.5. Solubility in common organic solvents is significantly higher: in DMF and NMP, concentrations up to 200 mM are attainable with gentle warming (40 °C), while in THF and dichloromethane, the free acid is only sparingly soluble (≤ 5 mM), which limits the choice of coupling reagents for solution-phase peptide synthesis.
When Coupling to Hindered Amines Requires Specialized Activation Reagents
Direct amidation of the sterically congested carboxylic acid with primary or secondary amines using EDCI/HOBt mixtures often proceeds with yields below 40% because the 2,3-dimethoxyphenyl group obstructs approach to the activated ester intermediate. Phosphonium reagents such as PyBOP or PyAOP in the presence of N,N-diisopropylethylamine (DIEA) in DMF at 0 °C to room temperature raise conversion to 70–85% as determined by LC-MS analysis of crude reaction mixtures. For peptide couplings at the pyrrolidine nitrogen, pre-activation of the carboxylic acid as the pentafluorophenyl ester (Pfp-ester) enables acylation of sterically demanding N-methyl amino acids, a transformation that mirrors the difficult acylation of N-methylalanine in cyclosporin synthesis. The HATU/DIEA combination is effective for coupling to anilines, providing amides in 65–75% isolated yield after flash chromatography. When the amine component is a secondary aniline, the HATU/HOAt cocktail and 2,4,6-collidine base in N-methyl-2-pyrrolidone at 50 °C can overcome the reduced nucleophilicity. A comparison with the (2,4-dimethoxyphenyl) isomer reveals that the ortho-methoxy group in the 2,3-substituted system causes a ~2-fold reduction in reaction rate for HATU-mediated couplings with benzylamine, as monitored by 19F NMR when a fluorinated amine surrogate is employed. This steric effect, while synthetically challenging, imparts metabolic stability to the resulting amide bonds by shielding the scissile carbonyl from hepatic esterases and amidases. In solid-phase peptide synthesis, the free acid is loaded onto 2-chlorotrityl chloride resin in dichloromethane with DIEA, and further chain elongation proceeds with standard Fmoc chemistry using HBTU/HOBt activation, though double coupling cycles are advisable for resin-bound sterically hindered amines; acylation completion is monitored by Kaiser or chloranil tests. The product released after TFA cleavage regularly shows crude purities of >90% by HPLC, with the major impurity being deletion sequences arising from incomplete couplings.
Long-term storage outside inert atmosphere results in slow oxidation of the electron-rich dimethoxyphenyl ring, producing quinone-like chromophores that impart a tan discoloration. Thermogravimetric analysis (TGA) at a ramp rate of 10 °C·min⁻¹ under nitrogen shows no mass loss below 180 °C; a sharp exotherm registered by differential scanning calorimetry (DSC) at 210–215 °C corresponds to decarboxylation, which generates 4-(2,3-dimethoxyphenyl)pyrrolidine and CO₂. This thermal lability precludes melt-processing and necessitates lyophilization as the final drying step during manufacturing. Process-scale batches are produced under current Good Manufacturing Practice (cGMP) for intermediates, with full compliance to ICH Q7A. The compound is classified as a “non-mutagenic intermediate” based on negative Ames test results (OECD 471, strains TA98, TA100, TA1535, TA1537 and E. coli WP2 uvrA) performed on a representative lot, and the absence of structural alerts for DNA reactivity in DEREK Nexus and Sarah Nexus (version 6.4.0) in silico predictions. Workers handling the powder should observe local occupational exposure limits (OEL) of 100 µg·m⁻³ (8-hour TWA) and use approved particulate respirators, although the compound exhibits no acute dermal irritation in rabbit skin tests (OECD 404). Waste streams containing the substance are treated by adsorption onto activated carbon followed by incineration at ≥ 1100 °C with 2-second residence time to ensure complete destruction of halogen-free organic residues.
Thermal Degradation Pathways Under Forced Conditions and Their Analytical Fingerprints
Forced degradation studies carried out in accordance with ICH Q1A(R2) reveal two principal decomposition routes. In solution at pH 1.0 (HCl) and 80 °C over 48 h, the major degradation product (~15% area) is the decarboxylated pyrrolidine, identified by its protonated molecular ion at m/z 222.1 [M+H]⁺ in LC-MS and a characteristic high-field shift of the C3 methine resonance in 1H NMR (δ 2.95 ppm vs. δ 3.52 ppm in the parent acid). Under oxidative conditions (3% H₂O₂, 40 °C, 24 h), hydroxylation of the phenyl ring occurs regioselectively at the para-position to the pyrrolidine attachment, yielding a 4-hydroxy-2,3-dimethoxyphenyl derivative with a mass increase of 16 Da. Separation of this impurity from the parent compound on a C18 column requires a shallow gradient of 0.5% acetonitrile per minute, with the impurity eluting 0.8 min earlier. Mass balance is verified against external calibration with the parent standard, with recovery ≥ 95%. The analytical method’s specificity has been demonstrated by peak purity analysis (PDA detector, 200–400 nm, purity angle < purity threshold). For quantitation, the method uses a primary standard of the degradation product synthesized independently via Baeyer-Villiger oxidation of the aryl methyl ether precursor; its response factor at 210 nm relative to the parent is 1.07 ± 0.03. These data support the use of the compound in long-duration pharmacological assays where chemical integrity under physiological temperature and pH is an entry requirement.
